ovarian cancer

News

Utility of Genomic Instability Test Scores for Predicting PARP Response in Ovarian Cancer

06/03/2020

HRD test results used in published and ongoing clinical trials for PARP inhibitor-treatment of ovarian cancer are not equivalent, according to the results of a study presented at the American Society of Clinical...

HRD...

06/03/2020

Journal of Clinical Pathways

News

Impact of Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer

06/01/2020

On the first day of the American Society of Clinical Oncology (ASCO) Annual Meeting (May 30, 2020), Helen MacKay, MBChB, BSc, MRCP, MD, department of medicine, University of Toronto, provided the context and...

On the...

06/01/2020

Journal of Clinical Pathways

News

Genetic Testing Underutilized in Women With History of Ovarian Cancer

08/22/2017

JCP Editors

Less than 20% of patients with a history of ovarian cancer meeting National Comprehensive Cancer Network (NCCN) guidelines have undergone genetic testing or have discussed testing with their health care...

Less...

08/22/2017

Journal of Clinical Pathways

Research in Review

Novel Ovarian Cancer Subtypes Associated With Survival Outcomes Following Surgery

08/02/2017

JCP Editors

High-grade serous ovarian cancer can be categorized in five molecular subtypes associated with survival and surgical outcomes, according to research published in Clinical Cancer Research (August...

...

08/02/2017

Journal of Clinical Pathways

Research in Review

Mastectomy Not Cost-Effective for Most Patients With Ovarian Cancer

07/12/2017

JCP Editors

Risk-reducing mastectomy within five years of ovarian cancer diagnosis is not cost-effective compared with surveillance for patients with BRCA mutations, according to research published in Annals of Surgical Oncology...

...

07/12/2017

Journal of Clinical Pathways

Research in Review

Blood Flow Measurement Predicts Effectiveness of Ovarian Cancer Treatment

07/03/2017

JCP Editors

A tool for measuring blood flow and volume to ovarian cancer tumors accurately predicts the effectiveness of treatment, according to a recent study published in Clinical Cancer Research (June 2017;...

A tool...

07/03/2017

Journal of Clinical Pathways

Research in Review

Biomarker Associated With Worse Survival Outcomes in Ovarian Cancer

06/20/2017

JCP Editors

Women with advanced ovarian cancer who express a certain tumor antigen will likely experience a shorter progression-free survival (PFS) and overall survival (OS) than those without the antigen, according to research...

Women...

06/20/2017

Journal of Clinical Pathways

Research in Review

PARP Inhibitors Crucial to the Future of Ovarian Cancer Treatment

06/12/2017

JCP Editors

The treatment landscape in the coming decade for ovarian cancers will likely feature poly ADP ribose polymerase (PARP) inhibitors in combination with other treatments, according to reports from a recent...

The...

06/12/2017

Journal of Clinical Pathways

Research in Review

Prolonged PFS, QoL in Ovarian Cancer After Maintenance Therapy

06/08/2017

JCP Editors

Women with BRCA-mutated relapsed serous ovarian cancer who received maintenance therapy after platinum-based chemotherapy prolonged their progression-free survival (PFS) by almost 7 months, according to results of a...

Women...

06/08/2017

Journal of Clinical Pathways

Research in Review

Ovarian Cancer Associated With Out-of-Pocket Financial Burden

06/07/2017

JCP Editors

Patients receiving treatment for ovarian cancer experienced a significant out-of-pocket financial burden, due largely to cost disparities across treatment types and a lack of definitive treatment options, according...

...

06/07/2017

Journal of Clinical Pathways